UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/787,526	02/26/2004	C. Allen Chang	3102/2020	6448
35743 75	590 11/01/2006		EXAMINER	
	EVIN NAFTALIS & FRA	JONES, DAMERON LEVEST		
INTELLECTUAL PROPERTY DEPARTMENT 1177 AVENUE OF THE AMERICAS			ART UNIT	PAPER NUMBER
NEW YORK,	NY 10036		1618	

DATE MAILED: 11/01/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
Office Action Summary		10/787,526	CHANG ET AL.				
		Examiner	Art Unit				
		D. L. Jones	1618				
Period fo	The MAILING DATE of this communication or Reply	appears on the cover s	heet with the correspondence a	ddress			
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR RECHEVER IS LONGER, FROM THE MAILING insions of time may be available under the provisions of 37 CFR SIX (6) MONTHS from the mailing date of this communication. O period for reply is specified above, the maximum statutory per to reply within the set or extended period for reply will, by streply received by the Office later than three months after the med patent term adjustment. See 37 CFR 1.704(b).	B DATE OF THIS COM R 1.136(a). In no event, however riod will apply and will expire SIX atute, cause the application to be	MUNICATION. The may a reply be timely filed (6) MONTHS from the mailing date of this ecome ABANDONED (35 U.S.C. § 133).				
Status				•			
1) 又	Responsive to communication(s) filed on 1	7 August 2006.					
2a)□	This action is FINAL . 2b)⊠ This action is non-final.						
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Dispositi	ion of Claims						
4)⊠	4)⊠ Claim(s) <u>1,3,4,7-9,11,12 and 15-20</u> is/are pending in the application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.						
5)[Claim(s) is/are allowed.						
6)⊠							
7)🖂	Claim(s) 1, 3, 4, 7-9, 11, 12, and 15-20 is/a	are objected to.					
8)[Claim(s) are subject to restriction an	d/or election requireme	ent.				
Applicati	on Papers						
9)[The specification is objected to by the Exam	niner.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
	Replacement drawing sheet(s) including the cor	rection is required if the d	rawing(s) is objected to. See 37 C	FR 1.121(d).			
11)	The oath or declaration is objected to by the	Examiner. Note the at	tached Office Action or form P	TO-152.			
Priority ι	ınder 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a)(a) All b) Some * c) None of:						
	 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 						
	 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage 						
	application from the International Bureau (PCT Rule 17.2(a)).						
* S	See the attached detailed Office action for a	• • • • • • • • • • • • • • • • • • • •	•				
Attachme=	Wa)						
Attachment 1) Notice	u(s) e of References Cited (PTO-892)	4) [T] inte	erview Summary (PTO-413)				
2) D Notic	per No(s)/Mail Date						
3) Information Disclosure Statement(s) (PTO/SB/08) Space No(s)(Mail Date Cyber Statement (s) (PTO/SB/08)							
, ape	Paper No(s)/Mail Date 6) Other:						

ACKNOWLEDGMENTS

1. The Examiner acknowledges receipt of the amendment filed 8/17/06 wherein claims 1, 4, 9, and 12 are amended and claims 2, 5, 6, 10, 13, 14, and 21-46 are canceled.

Note: Claims 1, 3, 4, 7-9, 11, 12, and 15-20 are pending.

APPLICANT'S INVENTION

2. Independent claim 1 is directed to an excipient having the formula $X_m[X'(L')]_n$. Independent claim 9 is directed to a composition comprising a metal ion, M, complexed to an organic ligand, L and a complex salt excipient having the formula $X_m[X'(L')]_n$.

RESPONSE TO APPLICANT'S ARGUMENTS/AMENDMENT

3. The Applicant's arguments and/or amendment filed 8/17/06 to the rejection of the claims made by the Examiner under 35 USC 103 and/or 112 have been fully considered the rejections WITHDRAWN for the reasons set forth below.

112 Rejections

The 112, second paragraph, rejection is MOOT in view of the new grounds of rejection below.

Note: The rejection below will hopefully clarify that the claims are vague and indefinite because the formula of the excipient does not involve the variable L which Applicant is attempting to incorporate into defining the excipient.

103 Rejection

The 103(a) rejection is WITHDRAWN because Applicant has amended the claims to overcome the rejection.

NEW GROUNDS OF REJECTIONS

112 Written Description Rejection

4. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

5. Claims 1, 3, and 8 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claims 1, 3, and 8 disclose that 'L' is an organic ligand which may be L or another organic ligand which as a greater affinity for M than for calcium or zinc'.

However, the excipient formula appearing in independent claim 1, X_m[X'(L')]_n does not involve the variable L. Thus, based on the description set forth in the instant application, the variable L has not been described in such a way as to reasonably convey the metes and bounds of the claims and the limitations that Applicant is placing on the excipient based on the variable L which is absent in the excipient formula.

112 Rejections

- 6. The following is a quotation of the second paragraph of 35 U.S.C. 112:

 The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- 7. Claims 1, 3, 4, 7-9, and 11 rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1, 3, 4, 7, and 8: The claims as written are ambiguous because independent claim 1 is directed to an excipient having the formula $X_m[X'(L')]_n$. However, in defining the variables of the excipient formula, Applicant has included the variable L which is not included in the excipient formula. Instead, Applicant is attempting to further define the variable L' of the excipient by defining another structure M(L) which is not a portion of the excipient formula. Applicant is respectfully requested to delete the references to the variable L which do not appear in the excipient formula because is makes the claims confusing.

<u>Claims 3 and 11</u>: The claims are ambiguous because it is unclear what polyaminopolycarboxylic carboxylic acid derivatives Applicant is referring to which are compatible with the instant invention.

<u>Claim 9, line 3</u>: Did Applicant intend to insert 'and' after the phrase 'organic ligand, L'?

<u>Claims 1, 3, 8, 9, and 11</u>: The claims as written are ambiguous because of the phrase 'L' is an organic ligand which may be L or another organic ligand which has a greater affinity for M than for calcium or zinc". In particular, the phrase is ambiguous

Application/Control Number: 10/787,526

Art Unit: 1618

because it is unclear which organic ligands Applicant is referring to that are compatible

Page 5

with the instant invention (see independent claims 1 and 9). In addition (see

independent claim 1, for example), since it is the excipient that is being claim and the

formula of the excipient does not include the variable M, it is unclear what metals

Applicant is referring to and why Applicant is referring to the variables L and M which

are not involved in the formula of the excipient, $X_m[X'(L')]_n$.

CLAIM OBJECTIONS

8. Claims 12 and 15-20 are objected to as being dependent upon a rejected base

claim, but would be allowable if rewritten in independent form including all of the

limitations of the base claim and any intervening claims.

COMMENTS/NOTES

9. It should be noted that no prior art has been cited against the instant invention.

In particular, the claims are distinguished over the prior art of record because the prior

art neither anticipates nor renders obvious an excipient or composition having the

limitations as set forth in independent claims 1 and 9.

10. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to D. L. Jones whose telephone number is (571) 272-0617.

The examiner can normally be reached on Mon.-Fri., 6:45 a.m. - 3:15 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hartley can be reached on (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Primary Examiner

Page 6

Art Unit 1618

October 30, 2006